One Stop Shop for All Your Market Research Reports

Global Liquid Biopsy Market by Sample Type (Blood, Urine and Others), by Biomarker Type (CTC, Ctdna and Others), By Application (Lung Cancer, GIT Cancer, Breast, Colorectal, Lukemia, Prostate and Others), By End User Type (Hospitals, Academic Institutes, Diagnostic Labs and Cancer Research Centers) and by Region (North America, Latin America, Europe, APAC and MEA) - Size, Share, Growth, Trends, and Forecasts (2016–2024)

The global liquid biopsy market has been estimated at USD 418.5 in 2016 and is projected to reach USD 2,112.3 million by 2024, at a CAGR of 22.5% during the forecast period from 2016 to 2024. Liquid biopsy is a cutting-edge non-invasive cancer diagnosis process which uses biofluids such as blood, urine, plasma, cerebrospinal fluid (CSF) for detecting various cancers. The liquid biopsy test is useful for identifying cancer in early stages. The liquid biopsy test uses various biomarkers such as circulating tumour cells (CTC), circulating nucleic acids and exosomes as a biomarker for diagnosis of cancer. In the patient body, above-mentioned biomarkers can be released in to body fluids by cancer cells. Among all samples, blood sample is extensively used for diagnosis of various cancers such as lung cancer, GIT cancer, breast cancer, and leukemia. Urine and cerebrospinal samples are mainly used for detection of prostate and brain cancers respectively. Market Dynamics: Major drivers in the global liquid biopsy market are increasing prevalence of various cancers such as lung cancer, breast cancer, GIT cancers and prostate cancers and rising accessibility of advanced diagnosis procedures. These factors are expected to drive growth of the global liquid biopsy market during the forecast period. Other prominent driving factors are increasing oncologists preference towards liquid biopsy procedure for detecting cancer and increasing number of biotechnology and pharmaceutical companies research and developments to discover anti-cancer drugs.  In addition to this, increasing regulatory bodies’ approvals for various new non-invasive tests is also driving growth of global liquid biopsy market. However, high cost, reimbursement scenario and awareness are the major restraining factors are expecting to hamper global liquid biopsy market over the forecast period. By sample type, the global liquid biopsy market has been segment into blood, urine, and others (saliva, plasma, Cerebrospinal fluid (CSF)). By marker type, the global liquid biopsy market has been segment into circulating tumour Cells (CTCs), circulating tumour nucleic acids (ctNA), and exosomes. By disease indication, the global liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer (GIT), breast cancer, colorectal, prostate cancer, leukemia and others. In terms of value, Lung cancer disease indication segment is currently accounts for utmost revenue as compared to other disease indication segments in the global liquid biopsy market. While breast cancer and colorectal cancers disease indication segments are anticipated to contribute significant revenue in global liquid biopsy market by the end of 2024. By end user, the global liquid biopsy market has been segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. In terms of value, Cancer institute end user segment is expected to make significant incremental opportunity in global liquid biopsy market over the forecast period. The global liquid biopsy market has been segmented into five major regions: North America, Latin America, Europe, Europe, APAC, and Middle East & Africa (MEA). In 2016, North America is expected to account for the largest share and is expected to register a CAGR of 20.9% over the forecast period. This is owing to high adoption of novel advanced diagnostic technologies as well as increasing cancer prevalence in the U.S. and Canada. In terms of value, APAC region is estimated to be the fastest growing market and is expected to register a CAGR of 24.3% over the forecast period. By disease indication segment, Lung cancer disease segment in the APAC liquid biopsy market is expected to register a CAGR of 21.8% over the forecast period, owing to increasing lung cancer prevalence in this region. Major players in the global liquid biopsy market are BIOCEPT, INC., F. Hoffmann-La Roche Ltd., Qiagen N.V., Inc., Janssen Global Services, LLC,  MDxHealth SA, Natera, Inc., Silicon Biosystems, Sysmex Corporation, Trovagene, and Pathway Genomics Corporation.

Table of Content

1. Executive Summary 2. Assumptions and Acronyms 3. Research Methodology 4. Liquid Biopsy Market Overview 4.1. Liquid Biopsy Market Introduction 4.1.1. Market Definition 4.1.2. Market Taxonomy 4.2. Liquid Biopsy Market Dynamics (DROT) 4.2.1. Market Drivers 4.2.2. Market Restraints 4.2.3. Market Opportunities 4.2.4. Market Restraints 4.3. Pipeline Assessment, By Products 4.4. Product Penetration and Pricing Impact 5. Global Liquid Biopsy Market Forecast and Analysis, By Sample Type 5.1. Introduction 5.2. By Sample Type 5.2.1. Blood 5.2.2. Urine 5.2.3. Others (Plasma, Saliva, CSF) 6. Global Liquid Biopsy Market Forecast and Analysis, By Marker Type 6.1. Introduction 6.2. By Marker Type 6.2.1. CTCs (circulating tumor cells) 6.2.2. ctNA (circulating tumor nucleic acids) 6.2.3. Exosomes 7. Global Liquid Biopsy Market Forecast and Analysis, By End User 7.1. Introduction 7.2. By End User 7.2.1. Hospitals 7.2.2. Academic Institutes 7.2.3. Cancer Institutes 7.2.4. Diagnostic Centers 7.3. Market Attractiveness Analysis, By End User
Inquiry Before Buying
Request Sample
To choose the report type and your desired payment method

Share This Report

Our Clients

Latest Market News

US Economy Slowing Down – US GDP Slowdown Reversal Needed

The US economy is slowing down and there is need for a US GDP slowdown reversal pretty quick! In fact, over the first three months of 2017, GDP has expanded by only 0.7% against analysts’ expectations of 1%.  This is the slowest rate since the same three months in 2014. This information was published Friday by the U [...]

Read More
Facebook and Google Scam: Internet Giants Victims of Phishing Attack

A Facebook and Google scam has been revealed, where the two internet giants have been victims of what is claimed to be a $100 million (£77m) phishing attack. The initial report came out in March, when news was released of a phishing attack by Lithuanian Evaldas Rimasauskas on two major U.S. technology firms.   [...]

Read More
UK Economy Slowdown – UK GDP SlowDown in First Quarter

A UK economy slowdown has been reflected in a low growth rate of 0.3% in the first quarter of 2017. This is the slowest rate of UK growth since the same quarter of last year. According to the UK Office for National Statistics, this growth reduction related to a 0.3% growth rate in the service sector compared to 0.8% at [...]

Read More
Royal Bank of Scotland: RBS Quarterly Profit Report Looks Promising

The RBS quarterly profit report this week is the first to show the Royal Bank of Scotland out of the red since 2015. The report for the first quarter of 2017 showed the bank to have made £259 million profit. This is the first quarterly profit since the third quarter of 2015. This compares to a reported loss of £968 m [...]

Read More
Donald Trump to Renegotiate NAFTA Agreement

Donald Trump has stated to Canadian Prime Minister Justin Trudeau and Mexican President Enrique Pena Nieto that he wants to hasten a renegotiation of the terms of NAFTA (North American Free Trade Agreement) also known as the NAFTA Agreement [...]

Read More
Payment Mode
Single User $ 4575
Multi User $6575
Corporate User $8575
About this Report
Report ID 22379
Category
  • Medical Devices
  • Pharmaceuticals and Healthcare
Published on Upcoming
Number of Pages 200
Publisher Name Upcoming Reports
Over all Rating
"Rating is based on 689 reviews"